Related Experiment Video
Updated: Jun 5, 2025
Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate
Published on: January 17, 2018
Low serum S100A6 levels are associated RP-ILD risk in anti-MDA5-positive dermatomyositis
Wei Yan1, Qin Wu1, Yumeng Shi2
1Division of Rheumatology, Northern Jiangsu People's Hospital, Jiangsu, China.
Introduction:
Anti-MDA5-positive dermatomyositis (anti-MDA5-DM) is a rare autoimmune disease that often leads to rapid-progressive interstitial lung disease (RP-ILD). The lack of effective prediction and treatment methods makes RP-ILD a major risk factor for death in patients with this condition. S100A6 is a member of the S100 Ca2 + - binding protein family, which plays important roles in inflammation, tumor, injury, and fibroblast reparation. This study aims to explore the correlation between serum S100A6 and RP-ILD in anti-MDA5-DM, and to determine whether S100A6 can be used as a specific biomarker to predict RP-ILD.
Methods:
The authors enrolled 80 participants, including 20 healthy volunteers, 20 patients with anti-synthase syndrome, and 40 patients with anti-MDA5-positive dermatomyositis. Serum samples were collected and the levels of S100A6 were measured using ELISA. Logistic regression was used to analyze the relationship between serum S100A6 levels and RP-ILD, along with other clinical and laboratory parameters. RESULTS: Serum S100A6 levels were significantly lower in anti-MDA5-DM patients with RP-ILD than those without RP-ILD (odds ratio:0.393 (95% CI, 0.164-0.943, p = 0.036)). High serum S100A6 level was found to be a protective factor for RP-ILD. This study shows that high serum S100A6 level may be a protective factor for RP-ILD in anti-MDA5-DM patients. Serum S100A6 may be used as a specific biomarker to predict whether RP-ILD occurs in anti-MDA5-DM. Key Points • This research discovers and reports a biomarker (S100A6) for distinguishing potential RP-ILD in Anti-MDA5 positive dermatomyositis.
Insights
High serum S100A6 levels may protect against rapid-progressive interstitial lung disease (RP-ILD) in anti-MDA5-positive dermatomyositis (anti-MDA5-DM). This finding suggests S100A6 could be a biomarker for predicting RP-ILD risk in these patients.
Area of Science:
- Rheumatology
- Immunology
- Pulmonology
Background:
- Anti-MDA5-positive dermatomyositis (anti-MDA5-DM) is a rare autoimmune condition.
- Rapid-progressive interstitial lung disease (RP-ILD) is a severe complication of anti-MDA5-DM, often leading to fatal outcomes.
- S100A6, a calcium-binding protein, is implicated in inflammatory and fibrotic processes.
Purpose of the Study:
- To investigate the association between serum S100A6 levels and the presence of RP-ILD in patients with anti-MDA5-DM.
- To determine if S100A6 can serve as a predictive biomarker for RP-ILD in this patient population.
Main Methods:
- Serum S100A6 levels were quantified using ELISA in 80 participants (20 healthy volunteers, 20 anti-synthase syndrome patients, 40 anti-MDA5-DM patients).
- Logistic regression analysis was employed to assess the relationship between serum S100A6 and RP-ILD, considering clinical and laboratory factors.
Main Results:
- Serum S100A6 levels were significantly lower in anti-MDA5-DM patients who developed RP-ILD compared to those without RP-ILD.
- A high serum S100A6 level was identified as a protective factor against RP-ILD (odds ratio: 0.393, p=0.036).
Conclusions:
- Elevated serum S100A6 levels appear to confer protection against the development of RP-ILD in anti-MDA5-DM.
- Serum S100A6 holds potential as a specific biomarker for predicting RP-ILD in patients diagnosed with anti-MDA5-DM.
